The purpose of the present studies was to investigate the behavioral and
convulsant effects produced by the group I
metabotropic glutamate receptor agonist (S)-3,5-dihydroxyphenylglycine (
DHPG). Administered i.c.v. to mice, (S)-3,5-DHPG produced a behavioral syndrome consisting of scratching and/or facial grooming,
tremors, slow forelimb clonus, rearing, and falling that increased over the dose range of 10-400 nmol. The full syndrome, produced by 400 nmol of (S)-3,5-DHPG, was antagonized by the selective mGlu1 receptor antagonist
LY456236 but not by the mGlu5 receptor antagonist MPEP or the mGlu2/3 receptor antagonist
LY341495. The behaviors induced by the 400 nmol dose were not blocked by the
NMDA receptor antagonist
MK-801, but were attenuated by the non-
NMDA receptor antagonists
GYKI 52466 and
NBQX, and the Ca2+ mobilization inhibitor
dantrolene, but at motor-impairing doses. The scratching behaviors produced by 30 nmol of (S)-3,5-DHPG were antagonized by
LY456236 but not by MPEP,
LY341495 or
MK-801.
GYKI 52466 and
dantrolene, but not
NBQX, inhibited scratching at motor-impairing doses. Both 400 and 30 nmol of (S)-3,5-DHPG produced a
generalized seizure as recorded by surface EEG
electrodes.
LY456236 blocked the
seizures produced by 30 nmol but not by 400 nmol;
dantrolene was ineffective in blocking
seizures produced by either dose. The present findings suggest that (S)-3,5-DHPG produces an increase in excitation that is mediated by mGlu1 and non-
NMDA receptors.